Upstream Biosciences Inc. Expects Increased Interest From Big Pharma as FDA's Proposed Priority Review Voucher Program Is Implemented

VANCOUVER, BC--(Marketwire - June 10, 2008) - Upstream Biosciences Inc. (OTCBB: UPBS) announced today that the United States Food and Drug Administration's (FDA) proposed priority review voucher program to stimulate development of drugs for tropical diseases could increase and accelerate the financial returns for small companies with the most promising technologies.

Back to news